Peter Sguigna, MD, assistant professor of neurology at UT Southwestern Medical Center in Dallas, Texas, spoke on emerging research, innovative biomarkers, and expanding targeted therapies for patients living with NMOSD.
Peter Sguigna, MD
Advertisement
assistant professor of neurology at UT Southwestern Medical Center
Articles by Peter Sguigna, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
2
AD109 Accepted NDA, AXS-12 FDA Submission, Phase 2 CELIA Study Results
3
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3
4
POLARIS-AD Phase 3 Trial of PDE5 Inhibitor AR1001 Completes Treatment Phase With Favorable Safety Profile
5